2024
The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?
Vidal J, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, Salgado R, Bai Y, Rimm D, Hartman J, Acs B. The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably? EClinicalMedicine 2024, 78: 102928. DOI: 10.1016/j.eclinm.2024.102928.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor-infiltrating lymphocytesBreast Cancer Research FoundationPrognostic validityMetastatic triple-negative breast cancerDisease-free survival endpointsHazard ratioHost anti-tumor immunityScored tumor infiltrating lymphocytesTumor-infiltrating lymphocyte scoresTriple-negative breast cancer patientsYears median follow-upTumour-infiltrating lymphocyte assessmentAnti-tumor immunityMedian follow-upIndependent prospective cohortTNBC tumorsPrognostic potentialProspective cohortBreast cancerPrognostic performanceAnalytic cohortFollow-upSchool of MedicineSwedish Society for Medical Research
2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer 2020, 6: 15. PMID: 32436923, PMCID: PMC7217941, DOI: 10.1038/s41523-020-0155-1.Peer-Reviewed Original ResearchStromal tumor-infiltrating lymphocytesTriple-negative breast cancerMetastatic triple-negative breast cancerTumor-infiltrating lymphocytesClinical trialsBiomarker-driven clinical trialsPotential predictive biomarkersPotential risk factorsImmunotherapy trialsImmunotherapy responsePredictive biomarkersRisk factorsBreast cancerStratification factorsSpecific trialsIntegral biomarkerTrialsLymphocytesBiomarkersReliable assessmentReviewCancer